Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 May 1;161(5):472-481.
doi: 10.1001/jamadermatol.2025.0211.

3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial

H Peter Soyer  1 , Dilki Jayasinghe  2 , Astrid J Rodriguez-Acevedo  1   2 , Louisa G Collins  3   4 , Liam J Caffery  5 , David C Whiteman  6 , Brigid Betz-Stablein  1 , Sonya R Osborne  7 , Anna Finnane  4 , Caitlin Horsham  2 , Clare Primiero  1 , Leonard C Gray  2 , Monika Janda  2
Affiliations
Randomized Controlled Trial

3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial

H Peter Soyer et al. JAMA Dermatol. .

Abstract

Importance: Three-dimensional (3D) total-body photography (TBP) can support clinicians in monitoring and identifying changes to skin lesions in patients at high risk of melanoma.

Objective: To assess clinical outcomes between patients at high risk of melanoma receiving usual clinical care compared with those receiving usual care plus 3D TBP and sequential digital dermoscopy imaging (SDDI) every 6 months via teledermatology.

Design, setting, and participants: This randomized clinical trial was conducted at a research hospital in Brisbane, Australia, from April 2018 to October 2021, with adult patients (≥18 years) at high risk of developing a primary or subsequent melanoma. Data analysis was conducted from March 2022 to June 2024.

Intervention: Usual care plus 3D-TBP in person and SDDI via teledermatology at baseline, 6, 12, 18, and 24 months. The control group continued usual care and completed online surveys every 6 months.

Main outcome measures: Number and rates of excisions and/or biopsies of lesions suggestive of melanoma, and results of histopathologic testing.

Results: The analysis included 314 participants (mean [SD] age, 51.6 [12.8] years; 194 females [62%]) who completed all of the study procedures (158 in the intervention and 156 in the control). In all, 1527 excisions (905 intervention and 622 in the control) were performed among 226 participants (122 intervention and 104 controls), with 67 (4%) histopathologically confirmed as melanoma and 402 (26%) as keratinocyte cancer (KC). The mean (SD) number of lesions of any type excised per person was significantly higher in the intervention (5.73 [6.77]; 95% CI, 4.66-6.79) compared to the control group (3.99 [5.72]; 95% CI, 3.08-4.89; P = .02). Fewer melanomas were detected among the intervention group compared with the control (24 [35%] vs 43 [64%], respectively), and therefore, a lower incidence rate: 2.03 (95% CI, 1.30-3.02) vs 3.62 (95% CI, 2.62-4.88), respectively. After 1 year of follow-up, the intervention had a lower, but not statistically significant, rate of melanoma per person: 0.08 (95% CI, 0.03-0.13) compared with 0.16 (95% CI, 0.08-0.25) in the control; an average of 0.86 (95% CI, 0.55-1.16) vs 0.42 (95% CI, 0.24-0.59) KCs per person; and 2.01 (95% CI, 1.50-2.51) vs 1.39 (95% CI, 0.98-1.82) excisions or biopsies per person, respectively.

Conclusions and relevance: The results of this randomized clinical trial indicate that the addition of 3D-TPB and SDDI to usual care in a teledermatology setting without AI (artificial intelligence) increased the number and rate of skin excisions and biopsies performed. Further studies are required to compare teledermatology to usual care rather than adding it, and to study whether the use of AI can improve the teledermatology outcomes. Larger studies in multiple settings with a greater number of teledermatologists are needed. This study shows that conducting clinical trials in this setting is feasible.

Trial registration: anzctr.org.au Identifier: ACTRN12618000267257.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Soyer reported equity in e-derm-consult GmbH and MoleMap; consulting fees from Canfield Scientific Medical; and a patent (PCT/AU/2013/000394) licensed to Trajan Medical and Scientific via Uniquest, all outside the submitted work. Dr Whiteman reported travel support to attend the European Association of Dermato-Oncology meetings, and consulting fees from the Melanoma Network of New Zealand, outside the submitted work. Dr Betz-Stablein reported new employment by Canfield Scientific, which started after the submitted work. No other disclosures were reported.

Comment on

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR, et al. . Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. doi:10.3322/caac.21409 - DOI - PMC - PubMed
    1. Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now. CA Cancer J Clin. 2016;66(6):460-480. doi:10.3322/caac.21352 - DOI - PMC - PubMed
    1. Mangione CM, Barry MJ, Nicholson WK, et al. ; US Preventive Services Task Force . Screening for skin cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(15):1290-1295. doi:10.1001/jama.2023.4342 - DOI - PubMed
    1. Dieng M, Smit AK, Hersch J, et al. . Patients’ views about skin self-examination after treatment for localized melanoma. JAMA Dermatol. 2019;155(8):914-921. doi:10.1001/jamadermatol.2019.0434 - DOI - PMC - PubMed